On the morning of March 31, a seminar on the research and development of the single-drug 3CL targeting the treatment of new coronavirus infection Laritavir tablets was held in the Guangzhou laboratory. Previously, on March 23, the official website of the State Food and Drug Administration disclosed that in accordance with the special approval procedures for drugs, it conditionally approved the listing of the Class 1 innovative drug Laritevir Tablets (trade name: Le Ruiling) declared by Guangd...